Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
Recruiting · NCT07259512 · Interventional (participants receive a specific treatment) · Lead sponsor: Evi Liliek Wulandari
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Female or Male with age \>18 years old
- Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \< 40%)
Exclusion criteria
- Receiving hemodialysis therapy
- History of intolerance to ACE inhibitors
- Refractory hyperkalemia
- Pregnancy
- History of angioedema to ACE inhibitors
- Receiving sacubitril-valsartan therapy
- Receiving ARB therapy
- Hypotension with blood pressure \<90/60, or patients in shock.
Where it is running
2 locations listed.
- UNS Hospital - Kartasura, Central Java, Indonesia
- UNS Hospital - Kartasura, Central Java, Indonesia